Synthesis, solution conformation, and antibody recognition of oligotuftsin-based conjugates containing a β-amyloid(4-10) plaque-specific epitope

Marilena Manea, F. Hudecz, Michael Przybylski, G. Mező

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

One possible therapeutic approach to treat or prevent Alzheimer's disease (AD) is immunotherapy. On the basis of the identification of Aβ(4-10) (FRHDSGY) as the predominant B-cell epitope recognized by therapeutically active antisera from transgenic AD mice, conjugates with defined structures containing the epitope peptide attached to a tetratuftsin derivative as an oligopeptide carrier were synthesized and their structure characterized. To produce immunogenic constructs, the Aβ(4-10) epitope alone or flanked by a- or β-alanine residues was attached through an amide bond to the tetratuftsin derivative (Ac-[TKPKG]4-NH2) or to a carrier peptide elongated by a promiscuous T-helper cell epitope (Ac-FFLLTRILTIPQSLD-[TKPKG] 4-NH2). The conformational preferences of the carrier and conjugates were examined by CD spectroscopy in water and in 1:1 and 9:1 TFE:water mixtures (v/v). We found that the presence of flanking dimers in the conjugates had no effects on the generally unordered solution conformation of the conjugates. However, conjugates with an elongated peptide backbone exhibited CD spectra indicative for a partially ordered secondary structure in the presence of TFE. Comparative ELISA binding studies, using monoclonal antibody raised against the β-amyloid (1-17) peptide, showed that conjugates with T-helper cell epitope in the carrier backbone exhibited decreased monoclonal antibody recognition. However, we found that this effect was compensated in conjugates comprising the Aβ(4-10) B-cell epitope with the β-alanine dimer flanking regions at both N- and C-termini. Results suggest that modification of the B-cell epitope peptide from Aβ with rational combination of structural elements (e.g. conjugation to carrier, introduction of flanking dimers) can result in synthetic antigen with preserved antibody recognition.

Original languageEnglish
Pages (from-to)921-928
Number of pages8
JournalBioconjugate Chemistry
Volume16
Issue number4
DOIs
Publication statusPublished - Jul 2005

Fingerprint

Epitopes
B-Lymphocyte Epitopes
Amyloid
Antibodies
Conformations
Dimers
Peptides
T-Lymphocyte Epitopes
Polytetrafluoroethylene
Alanine
Alzheimer Disease
Monoclonal Antibodies
Monoclonal antibodies
Derivatives
Cells
Oligopeptides
Synthetic Vaccines
Water
Amides
Immunotherapy

ASJC Scopus subject areas

  • Chemistry(all)
  • Organic Chemistry
  • Clinical Biochemistry
  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry

Cite this

Synthesis, solution conformation, and antibody recognition of oligotuftsin-based conjugates containing a β-amyloid(4-10) plaque-specific epitope. / Manea, Marilena; Hudecz, F.; Przybylski, Michael; Mező, G.

In: Bioconjugate Chemistry, Vol. 16, No. 4, 07.2005, p. 921-928.

Research output: Contribution to journalArticle

@article{2a0b3bce7f8141fd87b6d6350d70aca6,
title = "Synthesis, solution conformation, and antibody recognition of oligotuftsin-based conjugates containing a β-amyloid(4-10) plaque-specific epitope",
abstract = "One possible therapeutic approach to treat or prevent Alzheimer's disease (AD) is immunotherapy. On the basis of the identification of Aβ(4-10) (FRHDSGY) as the predominant B-cell epitope recognized by therapeutically active antisera from transgenic AD mice, conjugates with defined structures containing the epitope peptide attached to a tetratuftsin derivative as an oligopeptide carrier were synthesized and their structure characterized. To produce immunogenic constructs, the Aβ(4-10) epitope alone or flanked by a- or β-alanine residues was attached through an amide bond to the tetratuftsin derivative (Ac-[TKPKG]4-NH2) or to a carrier peptide elongated by a promiscuous T-helper cell epitope (Ac-FFLLTRILTIPQSLD-[TKPKG] 4-NH2). The conformational preferences of the carrier and conjugates were examined by CD spectroscopy in water and in 1:1 and 9:1 TFE:water mixtures (v/v). We found that the presence of flanking dimers in the conjugates had no effects on the generally unordered solution conformation of the conjugates. However, conjugates with an elongated peptide backbone exhibited CD spectra indicative for a partially ordered secondary structure in the presence of TFE. Comparative ELISA binding studies, using monoclonal antibody raised against the β-amyloid (1-17) peptide, showed that conjugates with T-helper cell epitope in the carrier backbone exhibited decreased monoclonal antibody recognition. However, we found that this effect was compensated in conjugates comprising the Aβ(4-10) B-cell epitope with the β-alanine dimer flanking regions at both N- and C-termini. Results suggest that modification of the B-cell epitope peptide from Aβ with rational combination of structural elements (e.g. conjugation to carrier, introduction of flanking dimers) can result in synthetic antigen with preserved antibody recognition.",
author = "Marilena Manea and F. Hudecz and Michael Przybylski and G. Mező",
year = "2005",
month = "7",
doi = "10.1021/bc0500037",
language = "English",
volume = "16",
pages = "921--928",
journal = "Bioconjugate Chemistry",
issn = "1043-1802",
publisher = "American Chemical Society",
number = "4",

}

TY - JOUR

T1 - Synthesis, solution conformation, and antibody recognition of oligotuftsin-based conjugates containing a β-amyloid(4-10) plaque-specific epitope

AU - Manea, Marilena

AU - Hudecz, F.

AU - Przybylski, Michael

AU - Mező, G.

PY - 2005/7

Y1 - 2005/7

N2 - One possible therapeutic approach to treat or prevent Alzheimer's disease (AD) is immunotherapy. On the basis of the identification of Aβ(4-10) (FRHDSGY) as the predominant B-cell epitope recognized by therapeutically active antisera from transgenic AD mice, conjugates with defined structures containing the epitope peptide attached to a tetratuftsin derivative as an oligopeptide carrier were synthesized and their structure characterized. To produce immunogenic constructs, the Aβ(4-10) epitope alone or flanked by a- or β-alanine residues was attached through an amide bond to the tetratuftsin derivative (Ac-[TKPKG]4-NH2) or to a carrier peptide elongated by a promiscuous T-helper cell epitope (Ac-FFLLTRILTIPQSLD-[TKPKG] 4-NH2). The conformational preferences of the carrier and conjugates were examined by CD spectroscopy in water and in 1:1 and 9:1 TFE:water mixtures (v/v). We found that the presence of flanking dimers in the conjugates had no effects on the generally unordered solution conformation of the conjugates. However, conjugates with an elongated peptide backbone exhibited CD spectra indicative for a partially ordered secondary structure in the presence of TFE. Comparative ELISA binding studies, using monoclonal antibody raised against the β-amyloid (1-17) peptide, showed that conjugates with T-helper cell epitope in the carrier backbone exhibited decreased monoclonal antibody recognition. However, we found that this effect was compensated in conjugates comprising the Aβ(4-10) B-cell epitope with the β-alanine dimer flanking regions at both N- and C-termini. Results suggest that modification of the B-cell epitope peptide from Aβ with rational combination of structural elements (e.g. conjugation to carrier, introduction of flanking dimers) can result in synthetic antigen with preserved antibody recognition.

AB - One possible therapeutic approach to treat or prevent Alzheimer's disease (AD) is immunotherapy. On the basis of the identification of Aβ(4-10) (FRHDSGY) as the predominant B-cell epitope recognized by therapeutically active antisera from transgenic AD mice, conjugates with defined structures containing the epitope peptide attached to a tetratuftsin derivative as an oligopeptide carrier were synthesized and their structure characterized. To produce immunogenic constructs, the Aβ(4-10) epitope alone or flanked by a- or β-alanine residues was attached through an amide bond to the tetratuftsin derivative (Ac-[TKPKG]4-NH2) or to a carrier peptide elongated by a promiscuous T-helper cell epitope (Ac-FFLLTRILTIPQSLD-[TKPKG] 4-NH2). The conformational preferences of the carrier and conjugates were examined by CD spectroscopy in water and in 1:1 and 9:1 TFE:water mixtures (v/v). We found that the presence of flanking dimers in the conjugates had no effects on the generally unordered solution conformation of the conjugates. However, conjugates with an elongated peptide backbone exhibited CD spectra indicative for a partially ordered secondary structure in the presence of TFE. Comparative ELISA binding studies, using monoclonal antibody raised against the β-amyloid (1-17) peptide, showed that conjugates with T-helper cell epitope in the carrier backbone exhibited decreased monoclonal antibody recognition. However, we found that this effect was compensated in conjugates comprising the Aβ(4-10) B-cell epitope with the β-alanine dimer flanking regions at both N- and C-termini. Results suggest that modification of the B-cell epitope peptide from Aβ with rational combination of structural elements (e.g. conjugation to carrier, introduction of flanking dimers) can result in synthetic antigen with preserved antibody recognition.

UR - http://www.scopus.com/inward/record.url?scp=22644434561&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22644434561&partnerID=8YFLogxK

U2 - 10.1021/bc0500037

DO - 10.1021/bc0500037

M3 - Article

C2 - 16029033

AN - SCOPUS:22644434561

VL - 16

SP - 921

EP - 928

JO - Bioconjugate Chemistry

JF - Bioconjugate Chemistry

SN - 1043-1802

IS - 4

ER -